HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Fluocinolone Acetonide (Capex)

Subscribe to New Research on Fluocinolone Acetonide

A glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732)

Also Known As:

Capex; Synalar; Fluonid; Fluotrex; Allergan Brand of Fluocinolone Acetonide; Alvadermo; Bioglan Brand of Fluocinolone Acetonide; Centrum Brand of Fluocinolone Acetonide; Co-Fluocin; Cortiespec; Derma-Smooth/FS; Flucinar; Fluocid; Fluodermo; Flurosyn; Flusolgen; Galderma Brand of Fluocinolone Acetonide; Gelidina; Geni Brand of Fluocinolone Acetonide; Grünenthal Brand of Fluocinolone Acetonide; Hill Brand of Fluocinolone Acetonide; Inexfa Brand of Fluocinolone Acetonide; Inkeysa Brand of Fluocinolone Acetonide; Jellin; Jellisoft; Medicis Brand 1 of Fluocinolone Acetonide; Medicis Brand 2 of Fluocinolone Acetonide; Rugby Brand of Fluocinolone Acetonide; Savage Brand of Fluocinolone Acetonide; Septa Brand of Fluocinolone Acetonide; Smaller Brand of Fluocinolone Acetonide; Synalar-HP; Synamol; Synemol; Syntex Brand of Fluocinolone Acetonide; Yamanouchi Brand of Fluocinolone Acetonide; medphano Brand of Fluocinolone Acetonide; Acetonide, Fluocinolone; Acetonide, Fluortriamcinolone; Co Fluocin; Derma Smooth/FS; Synalar HP; Fluortriamcinolone Acetonide; Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-

Networked: 282 relevant articles (25 outcomes, 35 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Jaffe, Glenn J: 13 articles (12/2015 - 07/2005)
2.	Kempen, John H: 9 articles (01/2016 - 04/2010)
3.	Holbrook, Janet T: 8 articles (01/2016 - 04/2010)
4.	Altaweel, Michael M: 7 articles (01/2016 - 04/2010)
5.	Jabs, Douglas A: 7 articles (01/2016 - 04/2010)
6.	Thorne, Jennifer E: 6 articles (12/2015 - 10/2011)
7.	Comstock, Timothy L: 6 articles (06/2015 - 11/2007)
8.	Sugar, Elizabeth A: 5 articles (01/2016 - 04/2010)
9.	Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group: 5 articles (12/2015 - 10/2011)
10.	Pearson, P Andrew: 5 articles (06/2015 - 06/2006)

Related Diseases

1.	Uveitis 07/01/2006 - "Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis." 12/01/2011 - "The MUST Trial is a multicenter randomized controlled CE trial evaluating a novel local therapy (intraocular fluocinolone acetonide implant) versus the systemic therapy standard of care for noninfectious uveitis. " 11/01/2000 - "In this report, we describe a pilot safety and efficacy trial of a novel sustained drug delivery system containing fluocinolone acetonide to treat patients with severe uveitis. " 05/01/2015 - "Risk factors associated with intraocular pressure increase in patients with uveitis treated with the fluocinolone acetonide implant." 08/01/2013 - "To report the 2-year incidence of raised intraocular pressure (IOP) and glaucomatous optic nerve damage in patients with uveitis randomized to either fluocinolone acetonide (FA) implants or systemic therapy. "
2.	Posterior Uveitis 03/01/2010 - "To evaluate the safety and efficacy of an intravitreal fluocinolone acetonide (FA) implant compared with standard therapy in subjects with noninfectious posterior uveitis (NIPU). " 09/01/2008 - "To evaluate the safety and efficacy of 0.59-mg and 2.1-mg fluocinolone acetonide (FA) intravitreous implants in noninfectious posterior uveitis. " 07/01/2005 - "To investigate the safety and efficacy of a fluocinolone acetonide intravitreal implant in the treatment of noninfectious posterior uveitis. " 06/01/2006 - "To report the interim 34-week safety and efficacy results of a 3-year study to evaluate an investigational intravitreal fluocinolone acetonide (FA) implant in patients with noninfectious posterior uveitis. " 06/01/2006 - "Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study."
3.	Psoriasis (Pustulosis Palmaris et Plantaris) 12/01/2004 - "This study also showed that the vehicle alone causes an improvement in the signs of psoriasis, but that the addition of 0.1% of the low potency steroid, fluocinolone acetonide, leads to a significantly better improvement." 09/01/2015 - "The aim of the current study was to develop and optimize Fluocinolone acetonide (FA) loaded nanostructured lipid carriers (NLC) and to evaluate its potential as topical delivery system for management of psoriasis. " 12/01/2004 - "This study was designed to demonstrate the efficacy, tolerance and safety of fluocinolone acetonide 0.01% in oil, compared to its vehicle, for the treatment of scalp psoriasis. " 09/01/2015 - "Design, characterization and skin permeating potential of Fluocinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis." 12/01/2004 - "Fluocinolone acetonide topical oil for scalp psoriasis."
4.	Melanosis (Freckles) 10/01/2013 - "Topical depigmenting agents were found to be the most effective in treating moderate-to-severe melasma, with combination therapies, such as triple-combination therapy (hydroquinone, tretinoin, and fluocinolone acetonide), yielding the best results. " 03/01/2013 - "The safety and efficacy of a novel skin-lightening cream (SLC) with 4% hydroquinone (HQ), which additionally contains 4 skin-brightening actives, was compared with a triple combination cream (TCC) with 4% HQ, 0.05% tretinoin, and 0.01% fluocinolone acetonide for the treatment of melasma under measures of sun protection. " 01/01/2005 - "This article describes a long-term, multicenter, open-label, 12-month study of once-daily fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05% (Tri-Luma Cream, hereinafter called TC [triple combination]) application in the treatment of melasma. " 05/01/2012 - "To compare clinical efficacy and safety of two 6-month Triple Combination (TC; containing fluocinolone acetonide, hydroquinone and tretinoin) maintenance regimens in subjects with moderate to severe melasma, after daily treatment up to 8 weeks. " 02/01/2011 - "Triple combination (TC) cream is a stable combination of fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% and is currently the only hydroquinone-containing drug approved by the Food and Drug Administration for the treatment of melasma. "
5.	Cataract (Cataracts) 05/01/2012 - "The intravitreal implant releasing fluocinolone acetonide significantly improved the best-corrected visual acuity (BCVA), but caused cataract progression and elevation of the intraocular pressure. " 05/01/2013 - "Fluocinolone acetonide implants can be considered, but have a high risk of cataract and sequelae from intraocular pressure rise. " 01/01/2016 - "Cataract surgery resulted in substantial, sustained, and similar visual acuity improvement in the eyes of patients with uveitis treated with the fluocinolone acetonide implant or standard systemic therapy." 10/01/2015 - "These results suggest that fluocinolone acetonide implant therapy is associated with a clinically important increased risk of glaucoma and cataract with respect to systemic therapy, suggesting that careful monitoring and early intervention to prevent glaucoma is warranted with implant therapy. " 01/01/2012 - "Post-cataract outcomes in patients with noninfectious posterior uveitis treated with the fluocinolone acetonide intravitreal implant."

Related Drugs and Biologics

1.	Tretinoin (Retinoic Acid)
2.	hydroquinone (Black and White)
3.	Triamcinolone Acetonide (Azmacort)
4.	Adrenal Cortex Hormones (Corticosteroids)
5.	arachis oil
6.	azelaic acid (Azelex)
7.	Propylene Glycol (1,2 Propanediol)
8.	Zidovudine (Retrovir)
9.	Silicones
10.	Oils

Related Therapies and Procedures

1.	Vitrectomy
2.	Cataract Extraction
3.	Cryotherapy (Therapy, Cold)
4.	Intraocular Lenses (Intraocular Lens)
5.	Cardiopulmonary Resuscitation (CPR)